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Introduction
Chronic obstructive pulmonary disease (COPD) is a major 
global health issue and is a leading cause of morbidity and 
mortality worldwide (1). Cigarette smoke exposure is a 
primary cause of COPD and as smoking rates continue 
to rise in South-East Asia, the long disease latency of 
COPD will impact dramatically on global health care 
resources for many decades to come. It is also well 
established that environmental influences such as indoor 
and outdoor air pollutants contribute to the development 
of chronic lung disease in individuals with no smoking 
history (2). Pathologically, COPD manifests into impaired 
lung function and irreversible airflow obstruction as a 
consequence of small airways disease, excessive mucus 
production and the development of emphysema. The 
mechanisms that drive such deleterious remodelling 
processes are heterogeneous in nature; however it is evident 
that chronic inflammation and excessive oxidative stress 
become central to the progression of COPD (3).
Nature of persistent inflammation in COPD
Innate and adaptive immune cells accumulate with 
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progression of COPD. CD8+ T cells increase with disease 
severity and can release proteolytic enzymes that contribute 
to apoptosis of structural cells (4). CD4+ T cells, B cells 
and dendritic cells also aggregate into organised tertiary 
lymphoid organs (TLOs), which are found in COPD 
lungs and experimental models of chronic cigarette smoke 
exposure (5). The significance of these lymphoid follicles 
has yet to be established, where B cell accumulation may 
prove to be beneficial in terms of antibody production to 
colonising and invading pathogens, or detrimental through 
autoantibody production against lung tissue antigens (6). 
Of note, targeted disruption of TLO formation through 
neutral i sat ion of  CXCL13 does  not  reduce lung 
inflammation and alveolar enlargement in a chronic smoke 
exposure model (7), suggesting that immune cells of the 
innate system are sufficient to drive pathological changes 
that occur in COPD. In addition, inflammation does 
not fully resolve even when individuals with COPD stop 
smoking. Inflammation persists in bronchial biopsies and 
in sputum samples from COPD patients when compared 
to asymptomatic smokers (8-10). In particular, neutrophilic 
inflammation remained elevated in COPD subjects who 
had ceased smoking for at least one year (8-10). Given 
that neutrophils are a relatively short-lived immune cell; 
their persistence in COPD indicates that there is continual 
recruitment of leukocytes into the airways even when the 
primary insult of smoke exposure is removed.
Smoke exposure is particularly deleterious to host 
immunity against respiratory pathogens. Macrophage 
function is compromised in a microenvironment where 
there is excessive oxidative stress, leading to a deficiency in 
phagocytosis of bacteria (11) and efferocytosis of apoptotic 
cells (12). Free radicals have been shown to impair clearance 
mechanisms by directly causing cytoskeletal instability and 
carbonyl modification of pseudopodia (13-15). Macrophages 
also interact with carbonyl-adduct modified extracellular 
matrix proteins, which impair their ability to clear 
apoptotic neutrophils (16). Reduced macrophage function 
is consistent with high colonisation rates in COPD, where 
up to 50% of COPD patients are chronically colonized 
with microorganisms including Haemophilus influenzae, 
Streptococcus pneumoniae and Moraxella catarrhalis (17,18). 
Impaired immunity to respiratory pathogens also contributes 
to susceptibility to acute exacerbations of COPD (AECOPD), 
which are predominately caused by a new respiratory 
pathogen that is different to the colonized pathogen (19). 
AECOPDs result in a more rapid decline in lung 
function (20), which adversely affects mortality rates (21) 
and health related quality of life (22). Viral infections are 
a common cause of AECOPDs (23,24), as are bacterial 
infections, which are associated with a marked increase in 
neutrophilic inflammation (25).
Bacterial colonization and AECOPDs contribute to 
persistent inflammation of the airways, as neutrophils 
and monocytes are recruited from the circulation in an 
attempt to clear the invading pathogens. Since resident 
airway macrophages in COPD have a reduced capacity to 
clear efferocytic neutrophils, the emergence of necrotic 
neutrophils may further facilitate a vicious cycle of 
inflammation through release of endogenous damage 
associated molecular patterns (DAMPs). For example, 
degranulating necrotic bodies release neutrophil elastase, 
which localize to lung elastic fibers in emphysematic 
patients and degrades extracellular matrix components (26). 
Excessive neutrophil elastase activity can also promote 
the release of mucins through Epidermal Growth 
Factor Receptor (EGFR)-dependent mechanisms (27). 
Furthermore, increased EGFR transactivation augments 
inflammatory responses initiated by rhinovirus infection 
in bronchial epithelial cells (28). Necrotic neutrophils also 
release High-Mobility Group Box-1 (HMGB1), which is a 
DNA binding protein that is elevated in COPD airways (29). 
HMGB1 can synergize with microbial products and 
endogenous cytokines to enhance inflammation through 
Toll Like Receptor (TLR) (30,31) and Receptor for 
Advanced Glycosylation End (RAGE) (29) dependent 
mechanisms. Hence, COPD airways represent a highly 
complex milieu consisting of inhaled irritants, respiratory 
pathogens and endogenous mediators released from 
damaged tissue, which collectively drive excessive host 
immunity and sterile inflammation.
Pro-resolution mediators promote catabasis in 
the inflamed airway
The ongoing recruitment of leukocytes from the 
circulation is consistent with increased local production of 
CXCL chemokines in COPD including IL-8 (CXCL8), 
ENA78 (CXCL5), GCP-2 (CXCL6) and GRO isoforms 
(CXCL1-3) (32,33). The CXCR family of G coupled 
protein receptors (GPCR) binds to these endogenous 
chemokines, where CXCR2 is the cognate receptor for 
this family (34). There is also a high degree of redundancy 
in leukocyte mobilization as alternate mediators such as 
leukotriene B4 (LTB4) are associated with neutrophilic 
inflammation in colonized COPD patients (35). These 
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pathways are essential to lung host immunity and 
are normally self-limiting through the activation of 
pro-resolution pathways. Pro-resolving mediators actively 
counterbalance inflammation by effectively switching 
off mechanisms that maintain leukocyte recruitment 
and survival. Eicosanoids such as lipoxins, resolvins and 
protectins and the protein termed Annexin A1 are integral 
to resolution of inflammation, [reviewed in (36-38)]; 
where there is a class switch of eicosanoid production 
from chemoattractants (such as the leukotriene LTB4) to 
pro-resolving mediators (such as lipoxin A4, LXA4) (39).
Lipoxins are synthesized in response to cell-cell interactions 
[reviewed in (40,41)]. In the lung, 15-lipoxygenase is 
expressed in epithelial cells and converts arachidonic acid 
to 15S-hydroxyleicosatetraenoic acid (15S-HETE). This 
metabolite is then taken up by neutrophils and converted to 
LXA4 by the enzyme 5-lipoxygenase (42). LXA4 opposes 
leukocyte migration and activation through multiple 
mechanisms including suppression of transendothelial (43) 
and transepithelial (44) migration and azurophilic 
degranulation (45). LXA4 can also directly target activated 
mucosal epithelial cells by opposing production of 
inflammatory cytokines (46). In vivo, administration of a 
stable analog of LXA4 reduced pulmonary inflammation 
and airway hyperreactivity in a murine model of asthma (47). 
Furthermore, this eicosanoid can directly contribute 
to tissue repair through the promotion of basal cell 
proliferation required for wound healing following mucosal 
injury (46). Another important anti-inflammatory role for 
LXA4 is its influence on macrophage function. Treatment 
with nanomolar concentrations of LXA4 stimulated more 
efficient efferocytosis of apoptotic neutrophils in human 
monocyte derived macrophages without provoking release 
of inflammatory mediators (48,49). LXA4-induced uptake 
of apoptotic neutrophils was reduced in macrophages from 
Fpr2 deficient mice, which is the mouse ortholog of the 
human ALX/FPR2 G-protein coupled receptor (GPCR) 
that potently interacts with lipoxins (50).
ALX/FPR2 is central to resolution of inflammation
In addition to lipoxins, the alternate anti-inflammatory 
mediators Annexin A1 and Resolvin D1 also interact 
with ALX/FPR2, implicating this receptor as an integral 
component of pro-resolution pathways. Accordingly, they 
display overlapping functions, where both LXA4 (51) 
and Annexin A1 (52) promote apoptosis of neutrophils 
as  a  mechanism of  resolving acute inf lammatory 
responses. Unlike lipid mediators derived from cell-
cell interactions, Annexin A1 is highly abundant in 
neutrophils where the 37kDa protein is localized to the 
cytoplasm and in gelatinase/azurophilic granules. Annexin 
A1 is a glucocorticoid-induced lipocortin that can be 
rapidly mobilized through degranulation of neutrophils. 
Cytoplasmic Annexin A1 is also subjected to post 
translational modifications such as phosphorylation, which 
facilitate translocation to the cellular membrane [reviewed 
in (52)]. In addition to promoting neutrophil apoptosis, 
Annexin A1 reduces neutrophil endothelial attachment 
and subsequent transmigration. Like LXA4, Annexin A1 
has also been shown to enhance efferocytosis of apoptotic 
neutrophils by macrophages [reviewed in (52)], thereby 
facilitating catabasis of the inflamed tissue to homeostasis.
Another family of mediators that target ALX/FPR2 
is the D series resolvins derived from the omega-3 fatty 
acid, docosahexaenoic acid (DHA) [reviewed in (53)]. 
Although there is relatively less information on the actions 
of D-series resolvins in lung diseases, there is emerging 
evidence to support an important role in resolution of 
lung inflammation. In a murine model of acute lung injury, 
treatment with stable derivatives of Resolvin D1 improved 
epithelial and endothelial integrity and reduced neutrophilic 
inflammation concurrently with reduced inflammatory 
cytokine secretion in the airways (54). In addition, 
aspirin-triggered Resolvin D1 (AT-RvD1) significantly 
reduced airway inflammation and enhanced macrophage 
phagocytosis in a murine asthma model (55). Furthermore, 
Resolvin D1 reduced neutrophilic lung inflammation, 
inflammatory cytokine production and phagocytosis in an 
acute cigarette smoke exposure model (56).
Is there an imbalance between inflammatory 
and pro-resolving mediators in COPD?
Given their important role in resolution of acute 
inflammation, any perturbation in the production of 
pro-resolving mediators can lead to the generation of 
pathogenic inflammatory conditions. Indeed, it has been 
shown that reduced production of LXA4 relative to 
cysteinyl leukotrienes is associated with the persistence of 
inflammation in severe asthma (57,58). Reduced levels of 
LXA4 are also observed in exhaled breath condensate during 
asthma exacerbations (59) and in the airway fluid of patients 
with cystic fibrosis (60). Since multiple mediators converge 
on ALX/FPR2, their relative abundance within the airway 
milieu of the chronically inflamed lung can profoundly 
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influence catabasis and restoration of homeostasis.
ALX/FPR2 belongs to the N-formyl peptide receptor 
(FPR) family, of which there are three human members 
(FPR1, ALX/FPR2 and FPR3). FPRs demonstrate wide 
tissue distribution, although ALX/FPR2 expression is 
particularly prominent on myeloid cells including neutrophils 
and monocytes (61). Airway mucosal epithelial cells also 
express ALX/FPR2 in a manner that is increased via COX-2 
dependent mechanisms in response to injury (46). Prominent 
staining is also observed on the apical and basolateral side of 
the epithelium of COPD airways (62).
ALX/FPR2 is a GPCR superfamily member characterized 
by seven putative TM domains that displays diverse ligand 
affinities that extend beyond interactions with lipoxins, series 
D-resolvins and Annexin A1. Accordingly, ALX/FPR2 can 
interact with over 30 ligands that can exert opposing biological 
actions (63). Hence, selective agonists are likely to bind 
with different affinities and given the diverse conformation 
of endogenous and synthetic ligands, are likely to bind 
to alternate regions of the receptor. Numerous receptor 
conformations can exist where ligand binding alters receptor 
formation, which facilitates alternate functional behaviors 
that control multiple downstream signaling pathways (64). 
This is true for ALX/FPR2, where agonist biased signaling 
can either promote inflammation or resolution contingent on 
alternate receptor conformations [reviewed in (65)]. Serum 
Amyloid A (SAA) and the anti-microbial peptide LL-37 
both interact with ALX/FPR2 and in complete contrast to 
pro-resolving mediators, promote neutrophil transmigration, 
activation and survival (summarized in Figure 1). Another 
high affinity ligand for ALX/FPR2 includes mitochondrial 
N-formylated hexapeptides  derived from NADH 
dehydrogenase and cytochrome c oxidase subunits (66). 
These formylated peptides are released from damaged 
cells and can interact with FPR1 and ALX/FPR2 (66). 
Although it is not known whether these ligands are elevated 
in COPD, there is increased mitochondrial dysfunction and 
cytochrome c oxidase levels in the skeletal muscle of COPD 
patients (67-69).
There are multiple mechanisms that may address why 
ALX/FPR2 receptors modulate cell responsiveness in 
a ligand-biased fashion. This includes the formation of 
homologous and/or heterologous receptor dimers and 
differential conformational ligand activation of specific 
receptor domains. The molecular nature of how ALX/FPR2 
downstream signaling pathways are activated in a ligand-
specific manner has yet to be fully characterized. However, 
there is evidence for conformational ligand activation. 
LXA4 has been shown to activate ALX/FPR2 by interacting 
with extracellular loop III and the associated transmembrane 
region (70), whereas SAA initiates extracellular loops I and 
II dependent signaling (71). In addition, SAA has recently 
been shown to promote ALX/FPR2 homodimerisation 
and activation of pro-survival pathways, which can be 
counteracted by Annexin A1 that promotes an alternative 
receptor conformation that engages pro-apoptotic 
pathways (72).
Conclusions
Since the accurate detection of lipid pro-resolution 
mediators in human tissue requires LC-LC-MS approaches 
that have only recently become available, there are currently 
relatively few studies demonstrating their presence in 
human tissue (73). Hence, there is a current knowledge gap 
in terms of whether there is a deficiency in production of 
pro-resolving mediators in COPD that facilitates a chronic 
inflammatory state, and advances in detection technology 
will reveal new insight here. Importantly, this should inform 
on the development of new classes of drugs to treat COPD 
away from conventional steroid-like anti-inflammatory 
approaches that can detrimentally dampen immunity 
leading to immunosuppression. Specialized pro-resolving 
mediators offer an alternative approach to switching off 
chronic inflammation and may concurrently boost beneficial 
host immunity and tissue repair mechanisms. Whilst the 
organic synthesis of pro-resolving lipid mediators can be 
challenging, chemically stable E-class resolvin analogs have 
been successfully synthesized and are currently in Phase III 
clinical trial for chronic inflammatory dry eye syndrome 
(Resolvyx Pharmaceuticals in partnership with Celtic 
Therapeutics).
Of interest, two human phenotypes have been described in 
response to cantharidin-induced skin blisters in male healthy 
volunteers involving distinct production of LXA4, which 
controlled the longevity and severity of the inflammation (74). 
The relative abundance of alternative ALX/FPR2 ligands may 
also directly influence the functional behavior of this complex 
receptor in COPD airways, where there is a rich milieu 
of microbial derived products and endogenous mediators. 
LL-37 (or hCAP-18) is a breakdown product of cathelicidin 
that promotes microbial killing through pore formation. 
LL-37 is also a chemoattractant for neutrophils, monocytes 
and lymphocytes via its actions on ALX/FPR2 (75). 
Since LL-37 levels are elevated in sputum samples from 
stable COPD patients (76) and are further increased during 
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bacterial AECOPDs (77), this normally protective molecule 
may contribute to persistent inflammation. Likewise, SAA, 
which has previously been characterized as a systemic 
biomarker for AECOPD severity (78), is prominently 
expressed in lung resection tissue from COPD patients (62). 
Using the same lung resection tissue, SAA transcript 
expression was also detected and found to be positively 
associated with the number of tissue neutrophils (79).
In addition to promoting neutrophil survival via ALX/
FPR2, SAA is a potent chemotactic factor that mediates 
migration of leukocytes (80) and can also stimulate 
expression of pro- inflammatory mediators under in vitro (81) 
and in vivo conditions (62). More recently, SAA was 
shown to promote the differentiation of monocyte derived 
macrophages into a pro-inflammatory phenotype that 
expresses higher levels of the TH17 polarizing cytokines, 
IL-6 and IL-1β in a manner that was dependent on 
CSF-1R signaling (82). Hence, the relative abundance 
and persistence of pro-inflammatory agonists such as 
SAA and LL-37 in COPD airways is likely to facilitate 
agonist biased signaling that favors leukocyte recruitment, 
activation and survival. The nature of this receptor also 
provides therapeutic opportunities to address ALX/FPR2 
conformations that may lead to pathogenic functions 
through the development of more stable analogs of lipoxins, 
D-series resolvins and cleavage resistant Annexin A1 
mimetics, which can override pro-inflammatory signals to 
initiate resolution of inflammation.
Figure 1 ALX/FPR2 and chronic inflammation in COPD. The ALX/FPR2 complex is expressed on leukocytes and the respiratory mucosa, 
where expression is particularly prominent on injured epithelial cells. The expression of two known ligands for ALX/FPR2, Serum Amyloid 
A (SAA) and LL-37 (hCAP-18) are known to be elevated in COPD and acute exacerbations of COPD. Mitochondrial hexapeptides 
released from damaged tissue also activate ALX/FPR2. SAA and LL-37 have been shown to initiate a pro-inflammatory response involving 
recruitment of neutrophils and monocytes. SAA can also promote neutrophil survival and release of inflammatory mediators from epithelial 
cells. In contrast, alternate ligands can bind to a different receptor region and promote distinct receptor conformations that translate to an 
opposing biological action. When the pro-resolving mediators LipoxinA4, Resolvin D1 and Annexin A1 interact with this receptor, they 
can actively initiate processes to reduce the influx of leukocytes and stimulate macrophages to clear exhausted immune cells and damaged 
tissue. SAA is disproportionally expressed relative to LXA4 in circulation during exacerbations and with the recent advance in technology 
to detect pro-resolving mediators in human tissue; it will be possible to explore this putative imbalance in COPD airways. With the 
ongoing development of more stable pro-resolving analogs, their therapeutic application may provide an opportunity to suppress chronic 
inflammation and clear damaged tissue to promote catabasis in the lung.
ALX/FPR2 
• SAA
• LL-37 (hCAP18)
• Mitochondrial 
hexapeptides
• Neutrophil transmigration
• Neutrophil survival
• Epithelial activation (release of 
IL8, GMCSF)
• Monocyte recruitment and 
activation
• Inhibits neutrophil transmigration
• Suppresses neutrophil survival
• Inhibits epithelial activation 
• Promotes macrophage-mediated 
phagocytosis/efferocytosis
LipoxinA4
Resolvin D1
Annexin A1
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